DexCom (NASDAQ:DXCM) Price Target Lowered to $90.00 at Stifel Nicolaus

DexCom (NASDAQ:DXCM) had its price objective decreased by Stifel Nicolaus from $132.00 to $90.00 in a report published on Friday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical device company’s stock.

Several other brokerages have also recently issued reports on DXCM. JPMorgan Chase & Co. cut DexCom from an overweight rating to a neutral rating and reduced their price objective for the stock from $145.00 to $75.00 in a research note on Friday. Morgan Stanley decreased their price objective on shares of DexCom from $132.00 to $120.00 and set an equal weight rating for the company in a research note on Monday, July 15th. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a buy rating in a research note on Wednesday, April 3rd. Royal Bank of Canada decreased their target price on shares of DexCom from $165.00 to $145.00 and set an outperform rating for the company in a research report on Friday. Finally, StockNews.com lowered shares of DexCom from a buy rating to a hold rating in a report on Monday, June 10th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of Moderate Buy and a consensus price target of $113.06.

DexCom Stock Performance

Shares of DexCom stock opened at $64.00 on Friday. The firm has a market capitalization of $25.45 billion, a P/E ratio of 41.29, a PEG ratio of 2.64 and a beta of 1.16. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company has a 50 day moving average price of $115.28 and a 200 day moving average price of $123.83.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 32.27%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.34 earnings per share. Sell-side analysts expect that DexCom will post 1.78 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,112 shares of company stock valued at $480,861. Company insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several large investors have recently made changes to their positions in DXCM. DSM Capital Partners LLC acquired a new stake in DexCom during the 4th quarter worth $28,000. Crewe Advisors LLC purchased a new position in shares of DexCom in the first quarter worth about $29,000. Valley National Advisers Inc. lifted its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Riverview Trust Co acquired a new position in DexCom during the first quarter worth about $32,000. Finally, MV Capital Management Inc. grew its stake in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.